

Specifying Human Platelet cAMP and cGMP Phosphodiesterase Inhibitory Activity of the Plants Used in Traditional Iranian Medicine for the Purpose of Erectile Dysfunction

¹M. Khanavi, ²H. Azimi, ³S. Ghiasi, ³S. Hassani, ^{3,4}R. Rahimi, ^{5,6}S. Nikfar,
⁷Y. Ajani, ^{1,4}M.R. Shams-Ardekani and ^{3,8}M. Abdollahi

¹Department of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

²Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

³Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran

⁴Department of Traditional Pharmacy, Faculty of Traditional Iranian Medicine,
Tehran University of Medical Sciences, Tehran, Iran

⁵Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy,
Tehran University of Medical Sciences, Iran

⁶Food and Drug Laboratory Research Center, Food and Drug Organization,
Ministry of Health and Medical Education, Tehran, Iran

⁷Institute of Medicinal Plants (ACECR), Karaj, Iran

⁸Department of Toxicology and Pharmacology, Faculty of Pharmacy,
Tehran University of Medical Sciences, Tehran, Iran

Abstract: In the present study, cAMP and cGMP phosphodiesterase inhibitory (PDEI) activities of the ethanolic extracts of nineteen plants of Traditional Iranian Medicine (TIM) with aphrodisiac effects were investigated. The plants were extracted in a similar way and then three concentrations (0, 1, 5 mg mL⁻¹) from each were tested for PDEI activity against control and sildenafil. Among plants tested, 8 including *Allium cepa*, *Trigonella foenum-graecum*, *Brassica rapa*, *Alpinia officinarum*, *Tribulus terrestris*, *Urtica pilulifera*, *Linum usitatissimum* and *Zingiber zerumbet* exhibited a significant dose-dependent cAMP-PDEI activity and 6 including *A. cepa*, *A. officinarum*, *T. terrestris*, *L. usitatissimum*, *Withania somnifera* and *Z. zerumbet* gave a remarkable dose-dependent cGMP-PDEI effects in comparison to control. Among tested herbs, *Zingiber officinalis* and *Peganum harmala* at dose of 5 mg mL⁻¹ demonstrated better cGMP-PDEI in comparison to sildenafil. The results of this study give idea for discovery of safe and better drugs in management of erectile dysfunction.

Key words: Phosphodiesterase inhibitor, sildenafil, traditional Iranian medicine, cAMP, cGMP

INTRODUCTION

Phosphodiesterases (PDEs) are a class of enzymes that exist in nearly all tissues regulating the second messengers cAMP and cGMP involving in many diverse physiological functions. PDE inhibitors (PDEIs) are used for management of clinical disorders such as dementia, depression, cardiovascular diseases, diabetes, chronic obstructive pulmonary diseases, colitis, toxicities, pulmonary hypertension and Erectile Dysfunction (ED) (Abdollahi *et al.*, 2003a, b, c; Jeon *et al.*, 2005; Khoshakhlagh *et al.*, 2007; Milani *et al.*, 2005). Inhibitors of PDE type 5 (PDE5I) i.e., sildenafil, vardenafil and tadalafil are now used in treatment of ED but have some common side effects like headache, flushing and blurred vision. As reviewed by Rahimi *et al.* (2010), there are many single and

combination herbal formulas in Traditional Iranian Medicine (TIM) for ED that needs experimental and clinical testing. The aim of the present study was to evaluate PDEI activity of the medicinal plants claimed to be beneficial for ED in TIM.

MATERIALS AND METHODS

Materials: Different parts of nineteen plants that were selected on the basis of TIM data were prepared from the clinic of Traditional Medicine, Tehran University of Medical Science (TUMS), Tehran, Iran, in May 2010. Voucher specimens have been deposited in the Central Herbarium of Medicinal Plants (ACECR, Karaj, Iran). All chemicals or reagents needed in this study were purchased from Sigma-Aldrich Company (Germany) unless otherwise stated.

Extraction method: Dried and semi powdered plants (20 g) were extracted using ethanol 80% (3×60 mL) at room temperature for a week. After removal of the solvent in the vacuum at 30°C, the residues were used for further analysis.

Assay of platelet cAMP and cGMP PDEI activity: The human platelets as a rich source of PDE enzymes were purchased from Tehran blood transfusion organization and stored at 25°C in a shaker during the process of experiment. An aqueous stock solution of 40 mM NaCl, 0.1 mM MnCl₂, 125 μM phenol red were prepared and the pH of this solution adjusted at 8.0. The assay mixture (200 μL) for control contained 53 μL of stock solution and 49 μL of platelets. Then cAMP and cGMP (1.9 mM) were added separately to the wells. The method is based on the absorbance level of the incorporating phenol red with titratable proton liberated from hydrolysis of cyclic nucleotide to corresponding 5'-phosphate ester by PDE (Frielle *et al.*, 1979). The 49 μL of plant extract that was dissolved in dimethyl sulfoxide (DMSO) 10% was added to 53 μL of stock solution and 49 μL of platelets and incubated for 20 min at 25°C. 49 μL of cAMP and cGMP (1.9 mM) were separately added to the wells and then after 5 min the absorbance of the test samples were read at 560 nm using a fluorescence microplate ELISA reader. The extracts with various concentrations ranging from 0.1 to 5 mg mL⁻¹ were tested. Each experiment was carried out in duplicate wells and the absorbance was read triplicate. Sildenafil was used as the standard solution and blank was 53 μL of stock solution and 49 μL of platelets with DMSO 10%. Three concentrations (0.1, 1, 5 mg mL⁻¹) of the extracts and sildenafil (40, 2, 20 μM) were tested.

Statistical analysis: Mean and standard error values were determined for all the parameters and the results were expressed as Mean±SEM. All data were analyzed using analysis of variance ANOVA followed by Newman Keuls. Differences between groups was considered significant when $p = 0.05$.

RESULTS AND DISCUSSION

Nineteen plants of TIM with aphrodisiac effects were selected and extracted with ethanol. The extraction ratio for each plant was shown in Table 1. As shown in Fig. 1, significant dose-dependent cAMP-PDEI activity were observed from eight plants including *Allium cepa*, *Trigonella foenum-graecum*, *Brassica rapa*, *Alpinia officinarum*, *Tribulus terrestris*, *Urtica pilulifera*, *Linum*

usitatissimum and *Zingiber zerumbet*. They showed the most cAMP-PDEI activity at 0.1 mg mL⁻¹, whereas the extracts of *Zingiber officinalis* and *Peganum harmala* demonstrated the most cAMP-PDEI effect at 5 mg mL⁻¹. The rest of the extracts showed similar cAMP-PDEI effect in three tested concentrations in comparison to sildenafil. As shown in Fig. 2, six plants including *Allium cepa*, *Alpinia officinarum*, *Tribulus terrestris*, *Linum usitatissimum*, *Withania somnifera* and *Zingiber zerumbet* showed significant dose-dependent cGMP-PDEI activity. The most cGMP PDEI effect was seen with 0.1 mg mL⁻¹ of these plants, while *Zingiber officinalis* and *Peganum harmala* had the most effect at 5 mg mL⁻¹. The rest of the extracts showed the same cGMP-PDEI effect in the three concentrations used in comparison to sildenafil. In this study, a total of 19 plants were screened for assaying inhibitory potential on platelets cAMP and cGMP PDEs. In comparison to sildenafil, 10 plants showed better cAMP-PDEI effect and 8 plants exhibited better cGMP-PDEI effect. These extracts showed the most PDEI activity at 0.1 mg mL⁻¹, whereas *Z. officinalis* and *P. harmala* showed a different pattern with the most PDEI effect at 5 mg mL⁻¹ that might be related to antiplatelet activity of both plants (Guh *et al.*, 1995; Im *et al.*, 2009; Thomson *et al.*, 2002). *A. cepa* and *P. harmala* have been previously shown for antiasthmatic effect (Duke, 2002; Wagner *et al.*, 1990). *A. cepa*, *B. rapa*, *L. usitatissimum*, *T. foenum-graecum*, *U. pilulifera*, *W. somnifera*, *Z. officinalis* and *Z. zerumbet* have already shown antioxidant activity (Hu *et al.*, 2007; Singh *et al.*, 2009; Kim *et al.*, 2006). *A. cepa*, *A. officinarum*, *P. harmala*, *T. foenum-graecum*, *W. somnifera*, *Z. officinalis* and *Z. zerumbet* have already shown anticancer or antitumor effects (Brown *et al.*, 2009; Huang *et al.*, 2005; Kaileh *et al.*, 2007; Lamchouri *et al.*, 1999; Singh *et al.*, 2009; Sur *et al.*, 2001; Yasukawa *et al.*, 2008). *A. cepa* and *Z. officinalis* are currently used as cardiogenic and cardiovascular (Shoji *et al.*, 1982; Park *et al.*, 2009). *A. officinarum* and *P. harmala* are found as antispasm (Duke, 2002; Gruenwald *et al.*, 2007). *A. officinarum*, *T. foenum-graecum*, *W. somnifera*, *U. pilulifera*, *Z. officinalis* and *Z. zerumbet* are used as anti-inflammatory agents (Aimbire *et al.*, 2007; Kavalali and Tuncel, 1997; Lee *et al.*, 2009; Vyas *et al.*, 2008; Zakaria *et al.*, 2010a). *P. harmala* and *T. terrestris* have shown vasodilator property (Berrougui *et al.*, 2006; Phillips *et al.*, 2006). *W. somnifera* and *Z. zerumbet* exhibited immunomodulatory action (Rasool and Varalakshmi, 2006; Yob *et al.*, 2011). *P. harmala* and *Z. zerumbet* were identified as analgesic (Farouk *et al.*, 2008; Zakaria *et al.*, 2010b). *P. harmala*, *Z. officinalis* and

Table 1: The plants used in TIM for erection dysfunction

Scientific name	Voucher number	Family name	Part used	Extraction ratio (%)	Persian name	Chemical constituents	Pharmacological effect
<i>Allium cepa</i> L.	1322	Liliaceae	Seed	10	Piaz	Alliins, fructosans, saccharose, othersugars, steroidesaponin, flavonoids (Gruenwald <i>et al.</i> (2007)), essential oil (DerMarderosian, 2008)	Antiasthmatic and antiallergic Wagner <i>et al.</i> (1990), antioxidant, anticancer Singh <i>et al.</i> (2009), cardiovascular support Park <i>et al.</i> (2009)
<i>Alpinia officinarum</i> Hance	1323	Zingiberaceae	Rhizome	15.2	Khulenjian	Volatile oil, diarylheptanoid, gingerole, starch, tannin, flavonoids Gruenwald <i>et al.</i> (2007), sesquiterpens (DerMarderosian, 2008)	Antispasmodic Gruenwald <i>et al.</i> (2007), enhancer of sperm count and motility DerMarderosian (2008), anti-inflammatory Lee <i>et al.</i> (2009), antitumor Yasukawa <i>et al.</i> (2008)
<i>Alyssum homolocarpum</i> Boiss	1324	Cruciferae	Seed	7.25	Ghodumeh	Mucilage Koochehi <i>et al.</i> (2010)	-
<i>Armenicaca vulgaris</i> Lam	1325	Rosaceae	Kernel	Bitter: 14.1, Sweet: 6.9	Zardalou	Mono- and polysaccharides, polyphenols, fatty acids and sterol derivatives, carotenoids, cyanogenicglucosides, volatile components Erdogan-orhan and Kartal (2011)	Antioxidant Yurt and Celik (2011.) antimicrobial, antimutagenic, inhibitory activity against several enzymes, cardioprotective, anti-inflammatory, antinociceptive (Erdogan-orhan and Kartal (2011)
<i>Brassica rapa</i> L.	1326	Cruciferae	Seed	12.7	Shalgham	Fatty oil, sterols Gruenwald <i>et al.</i> (2007)	Attenuation of oxidative stress Kim <i>et al.</i> (2006), aphrodisiac Qureshi <i>et al.</i> (1989)
<i>Daucus carota</i> L.	1327	Umbelliferae	Fruit	12.2	Gazar	Carotenoids, volatileoil, polyenes, mono and oligosaccharides Gruenwald <i>et al.</i> (2007), flavonoids (DerMarderosian, 2008), coumarin Gilani <i>et al.</i> (2000)	Relaxant, vasodilator, aphrodisiac DerMarderosian (2008), antinociceptive, anti-inflammatory Vasudevan <i>et al.</i> (2006), antispasmodic Gambhir <i>et al.</i> (1979), hypotensive Gilani <i>et al.</i> (2000)
<i>Descurainia sophia</i> L.	1328	Cruciferae	Seed	6.5	Khakshi	Essential oils (β-ocimene, menthol, neoisomenthyl acetate) Li <i>et al.</i> (2010), sulfur glycosides Sun <i>et al.</i> (2005)	Cardiotonic Fu-hua (1987), antitussive, diuretic, expectorant Mei-fang <i>et al.</i> (2008)
<i>Gundelia tournefortii</i> L.	1329	Compositae	Seed	4.2	Kangar	Caffeic acid derivatives, phenolic content Haghi <i>et al.</i> (2011)	Antioxidant Cornth <i>et al.</i> (2007)
<i>Lepidium sativum</i> L.	1330	Cruciferae	Seed	15.15	Shahi	Glucosinolates, cucurbitacins, cardiac steroids Gruenwald <i>et al.</i> (2007)	Antiasthmatic Gruenwald <i>et al.</i> (2007), anti-inflammatory, antipyretic, analgesic Al-yalya <i>et al.</i> (1994)
<i>Linum usitatissimum</i> L.	1331	Linaceae	Seed	10	Katan	Lignan Waldschlager <i>et al.</i> (2005), essential fatty acids (omega3) Kuhn and Winston (2000), sterole, triterpene, cyanogenic glycosides Blumenthal <i>et al.</i> (2000)	Antioxidant Hu <i>et al.</i> (2007), phytoestrogenic activity Waldschlager <i>et al.</i> (2005)

Table 1: Continued

Scientific name	Voucher number	Family name	Part used	Extraction ratio (%)	Persian name	Chemical constituents	Pharmacological effect
<i>Peganum harmala</i> L.	1332	Zygophyllaceae	Seed	6.63	Esfand	Harmin, harmalin, harmame, harmalol Hemmateenejad <i>et al.</i> (2006), vasicine, vasicinon Pulpati <i>et al.</i> (2008)	Analgesic Farouk <i>et al.</i> (2008), vasorelaxant Berrougui <i>et al.</i> (2006) antispasmodic, aphrodisiac, antiasmatic Duke (2002), anticancer Lamchouri <i>et al.</i> (1999), antiplatelet activity Im <i>et al.</i> (2009)
<i>Pinus gerardiana</i> Wall ex D. Don	1333	Pinaceae	Seed	12.55	Chalghouzeh	-	Diuretic DerMarderosian (2008), aphrodisiac
<i>Tribulus terrestris</i> L.	1334	Zygophyllaceae	Fruit	13.25%	Kharakhasak	Steroidal saponin Bedir <i>et al.</i> (2002), phenolic compound Ivanova <i>et al.</i> (2009), flavonoids	Malviya <i>et al.</i> (2011), management of ED, Gauthaman and Ganesan (2008) vasodilator Phillips <i>et al.</i> (2006)
<i>Trigonella foenum-graecum</i> L.	1335	Papilionaceae	Seed	13.8	Shanbalile	Bhutani <i>et al.</i> (1969) Mucilages, protein, steroidal saponins, sterols, flavonoids, trigonellin, volatile oil Gruenwald <i>et al.</i> (2007)	Anti-inflammatory Vyas <i>et al.</i> (2008), antitumor Sur <i>et al.</i> (2001), antioxidant Genet <i>et al.</i> (2002)
<i>Urtica pilulifera</i> L.	1336	Urticaceae	Seed	7.80	Anjoreh	-	Increasing sperm count and motility Irshaid and Mansi (2009) antioxidant Ozen <i>et al.</i> (2010), hypoglycemic activity Kavalali <i>et al.</i> (2003), anti-inflammatory Kavalali and Tuncel (1997)
<i>Withania somnifera</i> (L.) Dunal	1337	Solanaceae	Root	8.85	Bouzidan	Highly oxygenated steroid, alkaloids, flavonoglycosides, phenolic acid DerMarderosian (2008)	Immunomodulatory Rasool and Varaksham (2006), antioxidative Misra <i>et al.</i> (2009), aphrodisiac Malviya <i>et al.</i> (2011), anti-inflammatory, anticancer Kaleh <i>et al.</i> (2007)
<i>Zingiber officinalis</i> Roscoe	1338	Zingiberaceae	Rhizome	16.1	Zanjebil	Volatile oil, arylalkanes, gingerols, shogaols, gingerdiols, diarylheptanoids, starch Gruenwald <i>et al.</i> (2007), sesquiterpens DerMarderosian (2008), alkaloids Syamkumar <i>et al.</i> (2003)	enhancer of testosterone production DerMarderosian (2008), aphrodisiac Qureshi <i>et al.</i> (1989), anti- inflammatory Ambire <i>et al.</i> (2007), antioxidant Stoilova <i>et al.</i> (2007), antitumor Brown <i>et al.</i> (2009), cardiotoxic Shoji <i>et al.</i> (1982), antithrombotic Thomson <i>et al.</i> (2002), antiplatelet activity Guh <i>et al.</i> (1995)
<i>Zingiber zerumbet</i> (L.) Sm.	1339	Zingiberaceae	Rhizome	9.05	Zorombad	Zerumbone Huang <i>et al.</i> (2005), essential oil Zakaria <i>et al.</i> (2010a), humulene, monoterpenes, sesquiterpenoids, flavonoids, aromatic compounds Yob <i>et al.</i> (2011)	Antitumor Huang <i>et al.</i> (2005), anti-inflammatory Zakaria <i>et al.</i> (2010a), antinociceptive Zakaria <i>et al.</i> (2010b), antipyretic, hepatoprotective, immunomodulatory, antiplatelet aggregation, antioxidant Yob <i>et al.</i> (2011)




Fig. 1: Inhibitory effects of 10 extracts on cAMP-PDE activity *in vitro*. Values are expressed as Mean±SE. **Significantly different from Sildenafil (Sild) groups at (p<0.01)




Fig. 2: Inhibitory effects of 8 extracts on cGMP-PDE activity *in vitro*. Values are expressed as Mean±SE. **Significantly different from Sildenafil (Sild) groups at (p<0.01)

Z. zerumbet have shown antithrombotic and antiplatelet aggregation effects (Im *et al.*, 2009; Thomson *et al.*, 2002; Guh *et al.*, 1995; Yob *et al.*, 2011). *A. officinarum* and *U. pilulifera* increase motility and count of sperm (DerMarderosian, 2008; Irshaid and Mansi, 2009). *T. terrestris* is currently used in management of ED (Gauthaman and Ganesan, 2008). All of these therapeutic effects could be relevant to PDEI properties (Rahimi *et al.*, 2010). In our previous paper, it was indicated that main components of the plants with PDEI effects are flavonoids, alkaloids, saponins, lignans and coumarins (Rahimi *et al.*, 2010) that are seen in all 19 plants tested here (Table 1). Among tested herbs, *Z. officinalis* and *P. harmala* at 5 mg mL⁻¹ showed better cGMP-PDEI in comparison to sildenafil. *Z. officinalis* includes volatile oils, alkaloid and oleoresins (DerMarderosian, 2008; Gruenwald *et al.*, 2007;

Syamkumar *et al.*, 2003) while *P. harmala* contains alkaloid (Hemmateenejad *et al.*, 2006; Pulpati *et al.*, 2008).

CONCLUSION

The present study for the first time reports PDEI activities of TIM plants that is notable in the field of drug discovery for ED or other relevant diseases. It is required to complete animal and then clinical profile of these extracts. Also, combinative use of these plants may reveal more efficiency in ED with respect to synergetic effect of constituents.

ACKNOWLEDGMENT

This study was partly supported by a grant from Tehran University of Medical Sciences.

REFERENCES

- Abdollahi, M., A. Bahreini-Moghadam, B. Emami, F. Fooladian and K. Zafari, 2003a. Increasing intracellular cAMP and cGMP inhibits cadmium-induced oxidative stress in rat submandibular saliva. *Comp. Biochem. Physiol. C. Toxicol. Pharmacol.*, 135: 331-336.
- Abdollahi, M., T.S. Chan, V. Subrahmanyam and P.J. O'Brien, 2003b. Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin. *Mol. Cell Biochem.*, 252: 205-211.
- Abdollahi, M., F. Fooladian, B. Emami, K. Zafari and A. Bahreini-Moghadam, 2003c. Protection by sildenafil and theophylline of lead acetate-induced oxidative stress in rat submandibular gland and saliva. *Hum. Exp. Toxicol.*, 22: 587-592.
- Aimbire, F., S.C. Penna, M. Rodrigues, K.C. Rodrigues, R.A. Lopes-Martins and J.A.A. Sertie, 2007. Effect of hydroalcoholic extract of *Zingiber officinalis* rhizomes on LPS-induced rat airway hyperreactivity and lung inflammation. *Prostag. Leukotr. Essent. Fatty Acids*, 77: 129-138.
- Al-Yahya, M.A., J.S. Mossa, A.M. Ageel and S. Rafatullah, 1994. Pharmacological and safety evaluation studies in *Lepidium sativum* L. seeds. *Phytomedicine*, 1: 155-159.
- Bedir, E., I.A. Khan and L.A. Walker, 2002. Biologically active steroidal glycosides from *Tribulus terrestris*. *Pharmazie*, 57: 491-493.
- Berrougui, H., C. Martin-Cordero, A. Khalil, M. Hmamouchia, A. Ettaib, E. Marhuenda and M.D. Herrera, 2006. Vasorelaxant effects of harmine and harmaline extracted from *Peganum harmala* L. seeds in isolated rat aorta. *Pharmacol. Res.*, 54: 150-157.
- Bhutani, S.P., S.S. Chibber and T.R. Seshadri, 1969. Flavonoids of the fruits and leaves of *Tribulus terrestris*: Constitution of tribuloside. *Phytochemistry*, 8: 299-303.
- Blumenthal, M., A. Goldberg and J. Brinckmann, 2000. *Herbal Medicine: Expanded Commission E Monographs*. American Botanical Council, Austin, TX, pp: 519.
- Brown, A.C., C. Shah, J. Liu, J.T.H. Pham, J.G. Zhang and M.R. Jodus, 2009. Ginger's (*Zingiber officinale* Roscoe) inhibition of rat colonic adenocarcinoma cells proliferation and angiogenesis *in vitro*. *Phytother. Res.*, 23: 640-645.
- Coruh, N., A.G.S. Celep, F. Ogokece and M. Iscan, 2007. Antioxidant capacities of *Gundelia tournefortii* L. extracts and inhibition of glutathione S-transferase activity. *Food Chem.*, 100: 1249-1253.
- DerMarderosian, A., 2008. *The Review of Natural Products*. 5th Edn., Williams and Wilkins, USA.
- Duke, J.A., 2002. *Handbook of Medicinal Herbs*. 2nd Edn., CRC Press, Boca Raton, USA., ISBN: 9780849312847, Pages: 870.
- Erdogan-orhan, I and M. Kartal, 2011. Insights into research on phytochemistry and biological activities of *Prunus armeniaca* L. (apricot). *Food Res. Int.*, 44: 1238-1243.
- Farouk, L., A. Laroubi, R. Aboufatima, A. Benharref and A. Chait, 2008. Evaluation of the analgesic effect of alkaloid extract of *Peganum harmala* L: possible mechanisms involved. *J. Ethnopharmacol.*, 115: 449-454.
- Frielle, T., A.A. Crimaldi and C.J. Coffee, 1979. A continuous spectrophotometric assay for cyclic 3',5'-nucleotide phosphodiesterase. *Anal. Biochem.*, 97: 239-247.
- Fu-hua, L., 1987. Cardiac glycosides in traditional Chinese medicine. *J. Huazhong Univ. Sci. Technol.*, 7: 195-201.
- Gambhir, S.S., S.P. Sen, A.K. Sanyal and P.K. Das, 1979. Antispasmodic activity of the tertiary base of *Daucus carota*, Linn. seeds. *Indian J. Physiol. Pharmacol.*, 23: 225-228.
- Gauthaman, K and A.P. Ganesan, 2008. The hormonal effects of *Tribulus terrestris* and its role in the management of male erectile dysfunction an evaluation using primates, rabbit and rat. *Phytomedicine*, 15: 44-54.
- Genet, S., R.K. Kale and N.Z. Baquer, 2002. Alterations in antioxidant enzymes and oxidative damage in experimental diabetic rat tissues: effect of vanadate and fenugreek (*Trigonella foenum graecum*). *Mol. Cell. Biochem.*, 236: 7-12.
- Gilani, A.H., F. Shaheen, S.A. Saeed, S. Bibi, Irfanullah, M. Sadiq and S. Faizi, 2000. Hypotensive action of coumarin glycosides from *Daucus carota*. *Phytomedicine*, 7: 423-426.
- Gruenwald, J., T. Brendle and C. Jaenicke, 2007. *PDR for Herbal Medicine*. 4th Edn., Thomson Healthcare, USA., ISBN: 9781563636783, Pages: 1026.
- Guh, J.H., F.N. Ko, T.T. Jong and C.M. Teng, 1995. Antiplatelet effect of gingerol isolated from *Zingiber officinale*. *J. Pharm. Pharmacol.*, 47: 329-332.

- Haghi, G., A. Hatami and R. Arshi, 2011. Distribution of caffeic acid derivatives in *Gundelia tournefortii* L. food chem., 124: 1029-1035.
- Hemmateenejad, B., A. Abbaspour, H. Maghami, R. Miri and M.R. Panjehshahin, 2006. Partial least squares-based multivariate spectral calibration method for simultaneous determination of β -carboline derivatives in *Peganum harmala* seed extracts. Anal. Chim. Acta, 575: 290-299.
- Hu, C., Y.V. Yuan and D.D. Kitts, 2007. Antioxidant activities of the flaxseed lignin secoisolariciresinol diglucoside, its aglycone secoisolariciresinol and the mammalian lignans enterodiol and enterolactone *in vitro*. Food Chem. Toxicol., 45: 2219-2227.
- Huang, G.C., T.Y. Chien, L.G. Chen and C.C. Wang, 2005. Antitumor effects of zerumbone from *Zingiber zerumbet* in p-388d1 cells *in vitro* and *in vivo*. Planta Med., 71: 219-224.
- Im, J.H., Y.R. Jin, J.J. Lee, J.Y. Yu and X.H. Han *et al.*, 2009. Antiplatelet activity of β -carboline alkaloids from *Peganum harmala*: A possible mechanism through inhibiting PLC β 2 phosphorylation. Vascul. Pharmacol., 50: 147-152.
- Irshaid, F. and K. Mansi, 2009. Effects of leaf extract of *Urtica pilulifera* L. on male reproductive system of streptozotocin-diabetic rats. Am. J. Pharmacol. Toxicol., 4: 22-28.
- Ivanova, A., J. Serly, D. Dinchev, I. Ocsovszki, I. Kostova and J. Molnar, 2009. Screening of some saponins and phenolic components of *Tribulus terrestris* and *Smilax excelsa* as MDR modulators. *In Vivo*, 23: 545-550.
- Jeon, Y.H., Y.S. Heo, C.M. Kim, Y.L. Hyun, T.G. Lee, S. Ro and J.M. Cho, 2005. Phosphodiesterase: Overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol. Life Sci., 62: 1198-1220.
- Kaileh, M., W.V. Berghe, T. Boone, E. Essawi, T. and G. Haegeman, 2007. Screening of indigenous *Palestinian* medicinal plants for potential anti-inflammatory and cytotoxic activity. J. Ethnopharmacol., 113: 510-516.
- Kavalali, G. and H. Tuncel, 1997. Anti-inflammatory activities of *Urtica pilulifera*. Int. J. Pharmacol., 35: 138-140.
- Kavalali, G., H. Tuncel, S. Goksel and M.H. Hatemi, 2003. Hypoglycemic activity of *Urtica pilulifera* in streptozotocin-diabetic rats. J. Ethnopharmacol., 84: 241-245.
- Khoshakhlagh, P., M. Bahrololoumi-Shapourabadi, A. Mohammadirad, L. Ashtara-Nakhai, B. Minaie and M. Abdollahi, 2007. Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease: Molecular evidence for involvement of oxidative stress. Toxicol. Mech. Methods, 17: 281-288.
- Kim, Y.H., Y.W. Kim, Y.J. Oh, N.I. Back and S.A. Chung *et al.*, 2006. Protective effect of the ethanol extract of the roots of *Brassica rapa* on cisplatin-induced nephrotoxicity in LLC-PK 1 cells and rats. Biol. Pharm. Bull., 29: 2436-2441.
- Koocheki, A., S.A. Mortazavi, F. Shahidi, S.M.A. Razavi, R. Kadkhodae and J.M. Milani, 2010. Optimization of mucilage extraction from Qodume shirazi seed (*Alyssum homolocarpum*) using response surface methodology. J. Food Process. Eng., 33: 861-882.
- Kuhn, M.A. and D. Winston, 2000. Herbal Therapy and Supplements a Scientific and Traditional Approach. Lippincott, New York, pp: 2-15.
- Lamchouri, F., A. Settaf, Y. Cherrah, M. Zemzami and B. Lyoussi *et al.*, 1999. Antitumor principles from *Peganum harmala* seeds. Therapie, 54: 753-758.
- Lee, J.S., K.A. Kim, S.H. Jeong, S.G. Lee, H.J. Park, N.J. Kim and S. Lim, 2009. Anti-inflammatory, anti-nociceptive, and anti-psychiatric effects by the rhizomes of *Alpinia officinarum* on complete Freund's adjuvant-induced arthritis in rats. J. Ethnopharmacol., 126: 258-264.
- Li, J., X. Liu, F. Dong, J. Xu, Y. Zheng and W. Shan, 2010. Determination of the volatile composition in essential oil of *Descurainia sophia* (L.) webb ex prantl (Flixweed) by gas chromatography/mass spectrometry (GC/MS). Molecules., 15: 233-240.
- Malviya, N., S. Jain, V.B. Gupta and S. Vyas, 2011. Recent studies on aphrodisiac herbs for the management of male sexual dysfunction-a review. Acta Pol. Pharm., 68: 3-8.
- Mei-fang, M., L. Wen-hai and L. Jie, 2008. Experimental Research on Pharmacology and Acute Toxicology of *Descurainia Sophia* (L.) Webb ex Prantl Processed. Chin. Arch. Traditional Chin. Med.
- Milani, E., S. Nikfar, R. Khorasani, M.J. Zamani and M. Abdollahi, 2005. Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Comp. Biochem. Physiol. Part C, 140: 251-255.
- Misra, D.S., R. Maiti and D. Ghosh, 2009. Protection of swimming-induced oxidative stress in some vital organs by the treatment of composite extract of *Withania somnifera*, *Ocimum sanctum* and *Zingiber officinalis* in male rat. Afr. J. Tradit. Complement. Altern. Med., 6: 534-543.

- Ozen, T., Z. Collu and H. Korkmaz, 2010. Antioxidant properties of *Urtica pilulifera* root, seed, flower and leaf extract. *J. Med. Food.*, 13: 1224-1231.
- Park, S., M.Y. Kim, D.H. Lee, S.H. Lee and E.J. Baik *et al.*, 2009. Methanolic extract of onion (*Allium cepa*) attenuates ischemia/hypoxia-induced apoptosis in cardiomyocytes via antioxidant effect. *Eur. J. Nutr.*, 48: 235-242.
- Phillips, O.A., K.T. Mathew and M.A. Oriowo, 2006. Antihypertensive and vasodilator effects of methanolic and aqueous extracts of *Tribulus terrestris* in rats. *J. Ethnopharmacol.*, 104: 351-355.
- Pulpati, H., Y.S. Biradar and M. Rajani, 2008. High-performance thin-layer chromatography densitometric method for the quantification of harmine, harmaline, vasicine and vasicinone in *Peganum harmala*. *J. AOAC Int.*, 91: 1179-1185.
- Qureshi, S., A.H. Shah, M. Tariq and A.M. Ageel, 1989. Studies on herbal aphrodisiacs used in Arab system of medicine. *Am. J. Chin. Med.*, 17: 57-63.
- Rahimi, R., S. Ghiasi, H. Azimi, S. Fakhari and M. Abdollahi, 2010. A review of the herbal phosphodiesterase inhibitors: Future perspective of new drugs. *Cytokine*, 49: 123-129.
- Rasool, M. and P. Varalakshmi, 2006. Immunomodulatory role of *Withania somnifera* root powder on experimental induced Inflammation: An *in vivo* and *in vitro* study. *Vascular Pharmacol.*, 44: 406-410.
- Shoji, N., A. Iwasa, T. Takemoto, Y. Ishida and Y. Ohizumi, 1982. Cardiogenic principles of ginger (*Zingiber officinale* Roscoe). *J. Pharm. Sci.*, 71: 1174-1175.
- Singh, B.N., B.R. Singh, R.L. Singh, D. Prakash and D.P. Sing *et al.*, 2009. Polyphenolics from various extracts/fractions of red onion (*Allium cepa*) peel with potent antioxidant and antimutagenic activities. *Food Chem. Toxicol.*, 47: 1161-1167.
- Stoilova, I., A. Krastanov, A. Stoyanova, P. Denev and S. Gargova, 2007. Antioxidant activity of a ginger extract (*Zingiber officinale*). *Food Chem.*, 102: 764-770.
- Sun, K., X. Li, J.M. Liu, J.H. Wang, W. Li and Y. Sha, 2005. A novel sulphur glycoside from the seeds of *Descurainia sophia* (L.). *J. Asian Nat. Prod. Res.*, 7: 853-856.
- Sur, P., M. Das, A. Gomes, J.R. Vedasiromoni, N.P. Sahu, S. Banerjee, R.M. Sharma and D.K. Ganguly, 2001. *Trigonella foenum graecum* (Fenugreek) seed extract as an antineoplastic agent. *Phytother. Res.*, 15: 257-259.
- Syamkumar, S., B. Lowarence and B. Sasikumar, 2003. Isolation and amplification of DNA from rhizomes of turmeric and ginger. *Plant Mol. Biol. Rep.*, 21: 171-171.
- Thomson, M., K.K. Al-Qattan, S.M. Al-Sawan, M.A. Alnaqeeb, I. Khan and M. Ali, 2002. The use of ginger (*Zingiber officinale* Rosc.) as a potential anti-inflammatory and antithrombotic agent. *Prostaglandins Leukot Essent Fatty Acids*, 67: 475-478.
- Vasudevan, M., K.K. Gunnam and M. Parle, 2006. Antinociceptive and anti-inflammatory properties of daucus carota seeds extract. *J. Health Sci.*, 52: 598-606.
- Vyas, S., R.P. Agrawal, P. Solanki and P. Trivedi, 2008. Analgesic and anti-inflammatory activities of *Trigonella foenum-graecum* (seed) extract. *Acta Pol. Pharm.*, 65: 473-476.
- Wagner, H., W. Dorsch, T. Bayer, W. Brey and F. Willer, 1990. Antiasthmatic effects of onions: Inhibition of 5-lipoxygenase and cyclooxygenase *in vitro* by thiosulfinates and cepaenes. *Prostag. Leukotr. Essent. Fatty Acids*, 39: 59-62.
- Waldschlager, J., C. Bergemann, W. Ruth, U. Effmert and U. Jeschke *et al.*, 2005. Flax-seed extracts with phytoestrogenic effects on a hormone receptor-positive tumour cell line. *Anticancer Res.*, 25: 1817-1822.
- Yasukawa, K., Y. Sun, S. Kitanaka, N. Tomizawa, M. Miura and S. Motohashi, 2008. Inhibitory effect of the rhizomes of *Alpinia officinarum* on TPA-induced inflammation and tumor promotion in two-stage carcinogenesis in mouse skin. *J. Nat. Med.*, 62: 374-378.
- Yob, N.J., S.M. Jofry, M.M. Affandi, L.K. Teh, M.Z. Salleh and Z.A. Zakaria, 2011. *Zingiber zerumbet* (L.) smith: A review of its ethnomedicinal, chemical and pharmacological uses. *Evid. Based. Compl. Alt. Med.*, 10.1155/2011/543216.
- Yurt, B. and I. Celik, 2011. Hepatoprotective effect and antioxidant role of sun, sulphited-dried apricot (*Prunus armeniaca* L.) and its kernel against ethanol-induced oxidative stress in rats. *Food Chem. Toxicol.*, 49: 508-513.
- Zakaria, Z.A., A.S. Mohamad, M.S. Ahmad, A.F. Mokhtar and D.A. Israf, N.H. Lajis and M.R. Sulaiman, 2010a. Preliminary analysis of the anti-inflammatory activity of essential oils of *Zingiber zerumbet*. *Biol. Res. Nurs.*, 13: 425-432.
- Zakaria, Z.A., S. Mohamad, C.T. Chear, Y.Y. Wong, D.A. Israf and M.R. Sulaiman, 2010b. Antiinflammatory and antinociceptive activities of *Zingiber zerumbet* methanol extract in experimental model systems. *Med. Princ. Pract.*, 19: 287-294.